1-6 of 6
Marie-Laure Casadebaig
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase 3 Study (inMIND)

Laurie H. Sehn, Stefano Luminari, Christian W. Scholz, Kai Hübel, Antonio Salar, Shankara Paneesha, Bjorn E Wahlin, Panayiotis Panayiotidis, Hui-Peng Lee, Ana Jiménez Ubieto, Juan-Manuel Sancho, Tae Min Kim, Eva Domingo Domenech, Takahiro Kumode, Christina Poh, Catherine Thieblemont, Dries Deeren, Edwin de Wit, Michael Arbushites, Marie-Laure Casadebaig, Marek Trneny
Journal: Blood
Blood (2024) 144 (Supplement 2): LBA-1.
https://doi.org/10.1182/blood-2024-212970
Published: 2024
Journal Articles

KarMMa-4: Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T-Cell Therapy, in High-Risk Newly Diagnosed Multiple Myeloma

Saad Z. Usmani, MDMBBS,MBA, Jesus G. Berdeja, MD, Anna Truppel-Hartmann, MD, Marie-Laure Casadebaig, Honeylet Wortman-Vayn, Suresh G. Shelat, PhD, Steven Novick, MDPhD, Nina Shah, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 18–19.
https://doi.org/10.1182/blood-2020-139009
Published: 2020
Journal Articles

Durvalumab (Anti PD-L1) As Monotherapy or in Combination Therapy for Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL): A Subgroup Analysis from the Phase 1/2 Fusion NHL-001 Global Multicenter Trial

Carla Casulo, Armando Santoro, Kiyoshi Ando, Steven Le Gouill, Jia Ruan, MD PhD, John Radford, Luca Arcaini, Antonello Pinto, Reda Bouabdallah, Koji Izutsu, MD PhD, Simon Rule, Javier Munoz, MD, Marie-Laure Casadebaig, Brian Fox, Nils Rettby, Justine Dell'Aringa, Richard Delarue, Kathryn Newhall, Myron Czuczman, Guillaume Cartron
Journal: Blood
Blood (2019) 134 (Supplement_1): 5320.
https://doi.org/10.1182/blood-2019-124102
Published: 2019
Journal Articles

Outcomes Following Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma Patients at Risk of Bleeding Events Because of Multiple Comorbidities or Treatment: A Post-Hoc Subgroup Analysis of the SPRINT (MCL-002) Trial

Marek Trneny, Thierry Lamy, MDPhD, Jan Walewski, MD PhD, David Belada, MD PhD, Jiri Mayer, John A Radford, MB ChB, MRCP, MD FRCP, Wojciech Jurczak, MD PhD, Franck Morschhauser, Julia Alexeeva, MD, Simon A. Rule, MD, Boris V Afanasyev, Professor, Kamil Kaplanov, Antoine Thyss, MD, Alexej Kuzmin, MD, Sergey Voloshin, MD, Kazimierz Kuliczkowski, prof., Agnieszka Giza, MD, Noel Milpied, MD PhD, Caterina Stelitano, MD, Reinhard Marks, MD, Lorenz Trümper, MD, Tsvetan Biyukov, MD, Evelyn Barnett, Marie-Laure Casadebaig Bravo, MSc, Luca Arcaini, MD
Journal: Blood
Blood (2016) 128 (22): 2978.
https://doi.org/10.1182/blood.V128.22.2978.2978
Published: 2016
Journal Articles

Effectiveness of Lenalidomide in Patients with Mantle Cell Lymphoma Who Relapsed/Progressed after or Were Refractory/Intolerant to Ibrutinib: The MCL-004 Study

Michael Wang, MD, Peter Martin, MD, Tycel Phillips, MD, Andre Goy, MD, Izidore S Lossos, MD, Simon A. Rule, MD, Mehdi Hamadani, MD, Nilanjan Ghosh, MD PhD, Craig B. Reeder, MD, Evelyn Barnett, Marie-Laure Casadebaig Bravo, MSc, Stephen J. Schuster, MD
Journal: Blood
Blood (2016) 128 (22): 1786.
https://doi.org/10.1182/blood.V128.22.1786.1786
Published: 2016
Journal Articles

Phase II Randomized, Multicenter Study of Lenalidomide Vs Best Investigator’s Choice in Relapsed/Refractory Mantle Cell Lymphoma: Results of the MCL-002 (SPRINT) Study

Marek Trneny, Thierry Lamy, Jan Walewski, Wojciech Jurczak, David Belada, MD, Jiri Mayer, Prof., MD PhD, John Radford, Julia Alexeeva, Dzhelil Osmanov, Tsvetan Biyukov, Meera Patturajan, Marie-Laure Casadebaig Bravo, Luca Arcaini
Journal: Blood
Blood (2014) 124 (21): 626.
https://doi.org/10.1182/blood.V124.21.626.626
Published: 2014